Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique

With targeted therapies in oncology, we are faced with the emergence of new drug eruptions. Indeed, many of these new treatments have skin side effects different depending on the molecules used. These skin effects relate in particular inhibitors of EGF-R tyrosine kinase inhibitors " multitarget" and stabilizing the mitotic spindle. Sorafenib (Nexavar®), sunitinib (Sutent®) and imatinib (Gleevec®) are inhibitors of tyrosine kinase "multitarget". Their main cutaneous side effects are: hand-foot syndrome, subungual haemorrhages, change in hair texture, hair loss, dysesthesia and erythema of the face and scalp, xerosis, peri-orbital edema, cysts, keratoacanthomas, yellowing of the skin... Two anti-EGF-R are now commonly used: cetuximab (Erbitux®) and erlotinib (Tarceva®). Cutaneous toxicities are papulo-pustular eruptions, xerosis, fine hair, brittle and frizzy-like androgenetic alopecia, changes in hair color, trichomegaly ciliary, paronychia... The stabilizers of the mitotic spindle or taxanes are responsible for mucositis, stomatitis, handfoot syndrome, onycholysis, hyper-or hypopigmentation nail, alopecia, scleroderma... Work closely in order to recognize these symptoms earlier and provide comprehensive care of patients is essential. © Nouv Dermatol 2011

Lymphoplasmacytic plaque in children: Case report and literature review

We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm

Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study.

Tralokinumab, the first fully human monoclonal antibody that binds specifically to interleukin-13, was safe and effective for treating atopic dermatitis (AD) in clinical trials, but real-life experience is still limited. The objective of this study was to evaluate the effectiveness and safety of tralokinumab in severe AD in a real-life multicenter prospective cohort. Adult patients with severe AD were enrolled between January 2022 and July 2022 and received tralokinumab subcutaneously for 16 weeks. Objective and subjective scores were collected at baseline, weeks 6 and 16. Adverse events were reported throughout the study. Twenty-one patients were included. An improvement of at least 75% on the Eczema Area and Severity Index (EASI 75) was achieved in 66.7% of patients at week 16. The median objective and subjective scores at week 16 were significantly (p < 0.001) lower than those at baseline. Combination with cyclosporine was sometimes necessary at the beginning of treatment, and addition of upadacitinib was required for some patients with very severe disease during the treatment. The most frequent adverse events were flares of eczema (23.8%) and reactions at injection site (19.0%). No cases of conjunctivitis were reported. Four patients (19.0%) discontinued treatment. Tralokinumab is an effective first-line biotherapy for severe AD. However, therapeutic response may be progressive. Safety data were reassuring. Atopic dermatitis flares or reactions at the injection site may lead to discontinuation of treatment. A history of conjunctivitis on dupilumab is not a contraindication to the initiation of tralokinumab

Tralokinumab improves clinical scores in adolescents with severe atopic dermatitis: A real-life multicentric observational study.

Dear Editor,Atopic dermatitis (AD) usually develops during early child-hood but may continue into adolescence. The exact preva-lence of AD in adolescents remains unknown but recent longitudinal studies indicate a similar prevalence in child-hood and adolescence. [...